Emergent BioSolutions appoints Simon Lowry as Chief Medical Officer

From Nasdaq: 2024-11-04 08:51:39

Emergent BioSolutions Inc. appointed Simon Lowry as Chief Medical Officer, leading research and development starting on November 18. Lowry previously served as CEO of Mysthera Therapeutics AG. Jessica Perl was also promoted to General Counsel and Corporate Secretary. Emergent’s stock is trading at $9.01, down 1.21 percent on the NYSE during pre-market hours.



Read more at Nasdaq: Emergent BioSolutions Names Simon Lowry Chief Medical Officer